Revista Brasileira de Hematologia e Hemoterapia
versão impressa ISSN 1516-8484
HALLACK NETO, Abrahão E. et al. Risk stratification of large B-cell lymphomas. Rev. Bras. Hematol. Hemoter. [online]. 2006, vol.28, n.4, pp. 296-300. ISSN 1516-8484. http://dx.doi.org/10.1590/S1516-84842006000400016.
Diffuse large B-cell lymphoma is a heterogeneous clinical pathological entity which accounts for about 30% to 35% of all non-Hodgkin's lymphoma cases. It is considered to be aggressive due to the patient's short survival time when incorrect treatment is provided. Since 1993, treatment has been carried out according to IPI, which has been validated in several studies. However, since there are different responses from patients with the same IPI submitted to similar therapies, new prognostic markers are needed for these patients. As the biological nature of such lymphomas is becoming better known, other variables are starting to be used in order to stratify risk. In this review we will approach the key biological markers used as prognostic factors to treat diffuse Large B-Cell Lymphoma patients.
Palavras-chave : Large cell lymphoma; prognosis; review.